Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

By D. Kwekkeboom, W. D. de Herder, B. Kam, C. van Eijck, M. van Essen, P. Kooij, R. Feelders, M. O. van Aken, E. Krenning. Journal of Clinical Oncology, 2008

1,454 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/d65d152c58fbf035461729969d732733e286c074

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Zaknun
2. L. Bodei
3. Marianne Pavel
4. J. Mueller‐Brand
5. R. Baum
6. Dieter Hörsch
7. M. O'dorisio
8. T. M. O’Dorisiol

Citations in the corpus

• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, background): “Survival analyses have shown that patients with high sstr tumour expression at study entry, treated with either (177)LuDOTATATE or (90)Y-DOTATOC, show significantly higher objective responses that translate into significantly longer survival [48, 50].”